Literature DB >> 1501416

Childhood membranoproliferative glomerulonephritis type I: limited steroid therapy.

D M Ford1, D M Briscoe, P F Shanley, G M Lum.   

Abstract

Nineteen patients with biopsy proven membranoproliferative glomerulonephritis type I (MPGN I) and a minimum of three years of follow-up (mean 6.5 +/- 0.7 years) have been treated with an uncontrolled regimen of limited corticosteroids. Initial therapy ranged from 20 mg per os (po) every other day to 30 mg/kg/day i.v. for three consecutive days, depending on clinical disease severity. Therapy was then decreased based on each patient's improving clinical status. At diagnosis creatinine clearance (CCr) was less than 80 ml/min/1.73 m2 in 12 patients and less than 50 in 2. All patients had hematuria and proteinuria, with 15 in the nephrotic range. Hypertension, present at diagnosis in 13, developed in five others following institution of prednisone, and was controlled medically. Renal biopsy was repeated after two years of therapy prior to cessation of treatment (mean total treatment duration 38 +/- 3 months). Follow-up biopsy revealed decreased glomerular inflammatory activity in 88% of patients. All patients have now been off prednisone for 40 +/- 9 months. The mean CCr is 126 +/- 5 ml/min/1.73 m2. Eight patients have normal urinalyses. These data suggest that early therapy with a limited course of corticosteroids, and control of associated hypertension, may forestall progressive renal insufficiency in children with MPGN type I.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501416     DOI: 10.1038/ki.1992.232

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Long-term follow-up of atypical membranoproliferative glomerulonephritis: are steroids indicated?

Authors:  Teruo Fujita; Kandai Nozu; Kazumoto Iijima; Ichiro Kamioka; Kunihiko Yoshiya; Ryojiro Tanaka; Kiyoshi Hamahira; Koichi Nakanishi; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-10-25       Impact factor: 3.714

2.  Long-term follow-up of diffuse membranoproliferative glomerulonephritis type I.

Authors:  Takeshi Yanagihara; Mari Hayakawa; Junko Yoshida; Masami Tsuchiya; Toshisada Morita; Mutsumi Murakami; Yoshitaka Fukunaga
Journal:  Pediatr Nephrol       Date:  2005-03-22       Impact factor: 3.714

3.  Resolution of hepatitis B virus-related membranoproliferative glomerulonephritis after orthotopic liver transplantation.

Authors:  A Quan; A Portale; S Foster; J Lavine
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

4.  Transition of children with membranoproliferative glomerulonephritis to adolescence and adulthood.

Authors:  Kikuo Iitaka; Osamu Motoyama; Shinya Nakamura; Hiroe Koshino; Tadasu Sakai
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

5.  C3 nephritic factor associated with C3 glomerulopathy in children.

Authors:  Camille Nicolas; Vincent Vuiblet; Veronique Baudouin; Marie-Alice Macher; Isabele Vrillon; Nathalie Biebuyck-Gouge; Maud Dehennault; Sophie Gié; Denis Morin; Hubert Nivet; François Nobili; Tim Ulinski; Bruno Ranchin; Maria Chiarra Marinozzi; Stéphanie Ngo; Véronique Frémeaux-Bacchi; Christine Pietrement
Journal:  Pediatr Nephrol       Date:  2013-09-26       Impact factor: 3.714

6.  Non-nephrotic children with membranoproliferative glomerulonephritis: are steroids indicated?

Authors:  M Somers; S Kertesz; S Rosen; J Herrin; R Colvin; N Palacios de Carreta; M Kim
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

7.  Idiopathic membranoproliferative glomerulonephritis in Japanese children.

Authors:  K Iitaka; T Ishidate; M Hojo; S Kuwao; N Kasai; T Sakai
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

8.  Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy.

Authors:  J M Bergstein; S P Andreoli
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.